You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Dabrafenib mesylate New
Potent and selective Raf kinase inhibitor (IC50 values are 0.8, 3.2 and 5.0 nM for B-RafV600E, wild-type B-Raf and c-Raf, respectively). Exhibits selectivity for B-Raf over a panel of 270 other kinases. Arrests cell cycle in the G1 phase and inhibits growth of B-RafV600E mutant melanoma and colon cancer cells in vitro and in vivo. Orally bioavailable. Also inhibits NEK9 (IC50 <10 nM) and CDK16. Identified as targeting human host proteins that interact with SARS-CoV-2.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 615.66. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||3.25 mL||16.24 mL||32.49 mL|
|2.5 mM||0.65 mL||3.25 mL||6.5 mL|
|5 mM||0.32 mL||1.62 mL||3.25 mL|
|25 mM||0.06 mL||0.32 mL||0.65 mL|
References are publications that support the biological activity of the product.
Phadke et al (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol.Oncol. 12 74 PMID: 29112787
Gordon et al (2020) A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583 PMID: 32353859
Rheault et al (2013) Discovery of Dabrafenib: a selective inhibitor of Raf kinases with antitumor activity against B.Raf-driven tumors. ACS Med Chem Lett 4 358 PMID: 24900673
If you know of a relevant reference for Dabrafenib mesylate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Dabrafenib mesylate, Dabrafenib mesylate supplier, potent, selective, B-Raf, kinase, inhibitors, CDK16, NEK9, inhibits, chemotherapeutic, anticancer, SARS-CoV-2, COVID-19, severe, acute, respiratory, syndrome, Raf, Kinase, Cyclin-dependent, Coronavirus, 7223, Tocris Bioscience
Citations for Dabrafenib mesylate
Citations are publications that use Tocris products.
Currently there are no citations for Dabrafenib mesylate. Do you know of a great paper that uses Dabrafenib mesylate from Tocris? Please let us know.
Reviews for Dabrafenib mesylate
There are currently no reviews for this product. Be the first to review Dabrafenib mesylate and earn rewards!
Have you used Dabrafenib mesylate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.